A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BackgroundThe SUSTAIN-6 trial showed the cardiovascular disease (CVD) benefits of semaglutide among patients with type 2 diabetes mellitus (T2DM). We estimated the US population eligibility and preventable CVD events from semaglutide.MethodsUS adults…
Alzheimer's disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E () is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the mo…
AIM: To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. MATERIALS AND METHODS: In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults f…
PURPOSE: Oral semaglutide is the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) available for type 2 diabetes mellitus (T2DM) management, whose effectiveness and tolerability have extensively been demonstrated in the PIONEER clinical t…
OBJECTIVE: This study was designed to evaluate the effects of Semaglutide and adenosine on kidney protein expression in obese mice induced by a high-fat diet (HFD), to identify signaling pathways involved in the obesity-related glomerulonephropathy (…
BACKGROUND AND HYPOTHESIS: In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large high-quality real-world studies on the efficacy of weight-lowering interventions, including the g…
BACKGROUND: Coronary artery disease is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy and up to one-thirds with debilitating angina am…
AIMS: To report on the current evidence of early worsening of diabetic retinopathy (EWDR) in patients treated with new-generation antidiabetic agents, with a focus on glucagon-like peptide-1 receptor agonists (GLP1-RA). METHODS: A comprehensive analy…
IMPORTANCE: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications. OBJECTIVE: To report ophthalmic…
Bimagrumab is a monoclonal antibody that targets activin type II receptors, blocks myostatin and related proteins: it promotes muscle growth and prevents muscle loss, while causing weight loss. It has been effective in sporadic inclusion body myositi…
To address challenges such as limited loading capacity, restricted targeting precision, and low yield of natural exosomes as drug carriers, the fusion of liposomes and exosomes to create hybrid vesicles has emerged as a viable solution approach. Whil…
PURPOSE: The association between GLP-1 receptor agonists (GLP-1RA) and nonarteritic anterior ischemic optic neuropathy (NAION) remains unclear. Given the debilitating sequelae of NAION and rapid increase of GLP-1RA use, further research is essential…
The prevalence of obesity in older adults (people aged >60 years) is increasing in line with the demographic shift in global populations. Despite knowledge of obesity-related complications in younger adults (increased risk of type 2 diabetes, liver a…
A recent article highlighted the hepatic benefits of intermittent fasting, particularly during Ramadan. However, the rising use of glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (RAs) is altering…
BACKGROUND: The increasing prevalence of obesity represents a significant and growing challenge in orthopaedic surgery. This is particularly true for patients with morbid obesity, who have a significantly increased risk of postoperative complications…